Good
Mostly Aligned
Patient Risk:
Info
Summary
Most high-level statements (use to treat/prevent hypokalemia, need for monitoring, route-specific caution, and need for monitoring/adjustment of serum potassium) are consistent with the provided label excerpts. However, several claims are either too general or not directly supported by the supplied labeling text (e.g., specific side effect examples like palpitations/fainting, IV “urgent situations” wording, and specific monitoring of kidney function with ACE/ARB/potassium-sparing diuretics), and key administration instructions specific to extended-release tablets (with meals, swallow whole) are not reflected.
Category Scores
Accurate Statements
Potassium chloride (KCl) is a potassium salt used to treat low potassium levels (hypokalemia).
Consistent with label excerpt about potassium depletion treatment and serum potassium monitoring/adjustment (2.1). (Exact indication text not provided in the excerpt, but treatment of potassium depletion is stated.)
Potassium chloride works by supplying potassium.
Supported indirectly by the label focus on correcting low serum potassium (2.1: monitor serum potassium and adjust dosages accordingly).
Potassium chloride can be given as oral tablets or liquid.
Supported by label suggesting use of liquid potassium in patients with dysphagia/swallowing disorders (5.1) and by oral solid dosage form warnings (5.1).
IV administration of potassium chloride requires monitoring.
Supported by label requirement to monitor serum potassium and adjust dosages accordingly (2.1), and by statement that if serum potassium <2.5 mEq/L use IV potassium instead of oral (2.1).
Giving potassium too fast or at too high a dose can cause dangerous rhythm problems.
Supported generally by label emphasis on careful attention and monitoring/ECGs/electrolytes in patients with cardiac/renal disease or acidosis (2.1). (No explicit phrasing about “too fast/too high,” but label indicates careful monitoring including electrocardiograms.)
Concerning symptoms of potassium chloride adverse effects can include palpitations.
Not supported by the provided label excerpts.
Unsupported Statements
Potassium chloride (KCl) is used to prevent low potassium levels (hypokalemia).
The provided excerpt explicitly discusses treatment of potassium depletion and maintenance monitoring, but it does not explicitly state a preventive indication for KCl.
Potassium chloride is used in some settings to reduce the risk of heart rhythm problems that can occur when potassium is too low.
The excerpt mentions careful attention including electrocardiograms (2.1), but does not explicitly frame use as reducing risk of rhythm problems.
Potassium chloride can be given as IV (intravenous) potassium chloride.
The excerpt says to use intravenous potassium instead of oral when serum potassium <2.5 mEq/L, but it does not explicitly describe KCl products as “IV potassium chloride.”
IV potassium chloride is used in urgent situations when potassium must be corrected quickly under medical monitoring.
The excerpt specifies a threshold (<2.5 mEq/L) for using IV instead of oral and monitoring, but does not use “urgent situations” or “correct quickly” wording.
Potassium chloride is commonly used when low potassium is caused by diuretic medications.
No diuretic-specific cause/usage statement appears in the provided label excerpts.
Diuretic medications are often used for blood pressure or fluid retention.
Not addressed in the provided label excerpts.
Low potassium can be caused by vomiting or diarrhea.
Not addressed in the provided label excerpts.
Low potassium can be caused by poor intake or other medical conditions that affect potassium balance.
Not addressed in the provided label excerpts.
People typically report GI-related issues with oral potassium, such as stomach upset.
The excerpt discusses gastric irritation and ulcerative/stenotic lesions risk with solid oral forms, but does not include “stomach upset” as a typical adverse effect.
Concerning symptoms of potassium chloride adverse effects can include palpitations.
No symptom examples like palpitations are present in the provided excerpts.
Concerning symptoms of potassium chloride adverse effects can include severe weakness.
Not present in the provided excerpts.
Concerning symptoms of potassium chloride adverse effects can include fainting.
Not present in the provided excerpts.
Palpitations, severe weakness, or fainting require urgent medical attention.
Not present in the provided excerpts.
Potassium chloride can be dangerous if potassium levels are already high.
The excerpt does not explicitly discuss hyperkalemia as a risk of giving potassium when already high.
Risk of danger from potassium chloride increases in people with kidney disease or reduced kidney function.
The excerpt mentions careful attention in presence of renal disease and monitoring (2.1), but it does not explicitly say “risk increases” (it supports the need for careful attention rather than this risk framing).
In people with kidney disease or reduced kidney function, the body may not clear extra potassium well.
Not stated in the provided excerpts.
Certain medical situations where potassium can rise increase risk.
Not specified in the provided excerpts.
Overcorrecting potassium can lead to hyperkalemia.
Hyperkalemia is not mentioned in the provided excerpts.
Hyperkalemia can cause life-threatening heart rhythm abnormalities.
Not mentioned in the provided excerpts.
Potassium can rise when potassium chloride is used with certain drugs or in certain combinations.
Drug interaction information is not present in the provided excerpts.
Clinicians often check potassium and kidney function when KCl is prescribed alongside medications that affect the renin-angiotensin-aldosterone system (for example, ACE inhibitors or ARBs).
ACE inhibitors/ARBs are not referenced in the provided excerpts.
Clinicians often check potassium and kidney function when KCl is prescribed alongside some potassium-sparing diuretics.
Potassium-sparing diuretics are not referenced in the provided excerpts.
Clinicians often check potassium and kidney function when KCl is prescribed alongside other treatments that can increase potassium.
No such interaction-specific monitoring statements are present in the provided excerpts.
The chloride form of potassium matters because dosing and formulation differ by product.
No label excerpt supports this statement; the excerpt focuses on the product provided (extended-release tablets) and administration instructions.
Contradictions
Low
AI Statement
Potassium chloride can be given as IV (intravenous) potassium chloride.
Label Reference
2.1: “If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation.”
Important Omissions
For potassium chloride extended-release tablets: take with meals; do not take on an empty stomach due to potential gastric irritation (2.1 and 5.1).
Importance:
Moderate
Swallow extended-release tablets whole without crushing, chewing, or sucking (2.1).
Importance:
Moderate
Threshold-based guidance for route selection: if serum potassium <2.5 mEq/L, use intravenous potassium instead of oral (2.1).
Importance:
Moderate
Label-specific monitoring scope in at-risk patients includes careful attention to acid-base balance, volume status, electrolytes (including magnesium, sodium, chloride, phosphate, calcium), electrocardiograms, and clinical status (2.1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Because several statements (e.g., specific symptom examples, hyperkalemia details, and interaction-specific monitoring) are not supported by the provided label excerpts, the main risk is misinformation/omission of required administration and monitoring instructions for extended-release tablets (take with meals; swallow whole; route threshold; broader monitoring including ECGs and electrolytes).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of key administration instructions for potassium chloride extended-release tablets (take with meals; do not take on empty stomach; swallow whole) and lack of support for several detailed safety/interaction claims that are not present in the provided excerpts.
Suggested Improvement
Add the label-required administration instructions (with meals; not on empty stomach; swallow whole) and align safety/monitoring claims to the provided label text (monitor serum potassium, adjust dosages, and in at-risk patients monitor ECGs and broader electrolytes/acid-base/volume status). Remove or qualify statements not supported by the provided excerpts (symptom examples like palpitations/fainting; hyperkalemia causality; specific drug classes such as ACE inhibitors/ARBs and potassium-sparing diuretics).